Biotechnology
Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-06-07 08:00
8637
Arctic Vision Announces Exclusive Licensing Agreement with Olympic Ophthalmics for iTEAR®100 for the Treatment of Dry Eye Disease in Greater China, South Korea and ASEAN countries
ISSAQUAH, Wash. and SHANGHAI, June 7, 2021 /PRNewswire/ -- Arctic Vision, a clinical stage biotech company focusing on innovative ophthalmology therapies for pan-ocular diseases, and Olympic Ophthalmics, a U.S.-based medical technology company pioneering neuromodulation treatments for ophthalmic ...
2021-06-07 08:00
2760
Singapore/ US based TurtleTree ready to commercialize Human Lactoferrin as first major product
SINGAPORE, June 5, 2021 /PRNewswire/ -- TurtleTree, the pioneer of cell-based milk, is now preparing for the launch of its first commercially scalable product. Human Lactoferrin lately also referred to as pink gold because of it's amazing properties for boosting immunity, resistance to infections...
2021-06-05 01:32
4217
DiNovA's Israel Incubator officially opens its office in Caesarea
CAESAREA, Israel, June 4, 2021 /PRNewswire/ -- China headquartered DiNovA Medtech officially takes up residence in Caesarea Industry and Business Park for itsIsrael incubator, which continues to help augment the company's global footprint. DiNovA Medtech is not new to Israel. Its leadership team...
2021-06-04 14:00
2327
Elekta Nomination Committee's proposed Board of Directors for the 2021 Annual General Meeting
STOCKHOLM, June 4, 2021 /PRNewswire/ -- The Nomination Committee of Elekta (EKTA-B.ST) proposes that the 2021 Annual General Meeting re-elect Board members Laurent Leksell, who is also proposed to be re-elected as Chairman of the Board, Caroline Leksell Cooke, Johan Malmquist, Wolfgang Reim, Jan Se...
2021-06-04 13:56
2554
Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021
SHANGHAI and HONG KONG, June 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-06-04 08:00
3863
Vela Diagnostics Announces Collaboration with the National Cancer Centre of Singapore to Refine Novel Cancer Therapy
SINGAPORE, June 4, 2021 /PRNewswire/ -- Vela Diagnostics announced a collaboration with the National Cancer Centre ofSingapore (NCCS) to develop a molecular diagnostic assay to predict individual patients' responses to a cancer therapy called Epidermal Growth Factor Receptor (EGFR) tyrosine kinas...
2021-06-04 08:00
2494
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China clinical trial (PaTHway China Trial) of TransCon PTH Solution for Injection (TransCon™ parathy...
2021-06-04 02:00
2787
RWDC Industries Appoints New Chief Financial Officer
Thomas Aebischer brings 18 years of public and private company CFO experience and proven leadership track record to RWDC ATHENS, Georgia and SINGAPORE, June 3, 2021 /PRNewswire/ -- RWDC Industries, a biotechnology company on a mission to replace single-use plastics through innovative and cost-ef...
2021-06-03 22:00
3015
Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, June 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...
2021-06-03 17:09
5458
Peking University Biologics entering into Strategic Cooperation Agreement with Norwich Investment Limited
HONG KONG, June 3, 2021 /PRNewswire/ -- Peking University Biologics (hereinafter known as "PKU BIO") and Norwich Investment Limited (hereinafter known as "Norwich") announced today that both parties have entered into a Strategic Cooperation Agreement ("Agreement") to promote the business develop...
2021-06-03 16:29
3700
Clinical Trial Results of the BCMA CAR-T Co-developed by Innovent and IASO Biotherapeutics Commented in American Society of Hematology's Medical Journal "Blood"
SAN FRANCISCO, U.S. and SUZHOU, China, June 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major ...
2021-06-03 08:00
5975
Cell Care Joins the Generate Life Sciences Family to Create a Global Platform
The acquisition provides the companies with shared scientific knowledge and resources leading to a stronger foundation for advancing newborn stem cell banking and research MELBOURNE, Australia, June 3, 2021 /PRNewswire/ -- Cell Care, Australia's leading cord blood bank, today announced it has be...
2021-06-03 06:00
2902
First Patient Dosed in QBiotics & MSD Clinical Trial Collaboration for Unresectable Melanoma
* First patient dosed with QBiotics' lead oncology molecule tigilanol tiglate in combination with KEYTRUDA® (pembrolizumab) in a clinical trial collaboration with MSD (tradename of Merck & Co., Inc.,Kenilworth, NJ, USA) * The Phase Ib/IIa study will test the safety, optimal dose and tumour re...
2021-06-03 06:00
3023
Nanoform raises its mid-term business targets for 2025
HELSINKI, June 2, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, today announced its raised mid-term business targets for 2025. The new targets are as follows: * To nanoform annually at least 70 new active pharmaceutical ...
2021-06-02 21:42
1729
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement
NANJING, China and SAN DIEGO, June 2, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that they have entered into a strategic licensing agreement for Ligand's OmniAb®...
2021-06-02 21:00
9620
Portonbio announced strategic cooperation with KAEDI to accelerate the R&D and production of CAR-T drugs
SUZHOU, China, June 2, 2021 /PRNewswire/ -- On May 31, 2021, Porton Biologics Ltd. (hereinafter referred to as Portonbio) announced a strategic cooperation with Nanjing KAEDI Biotech, Inc. (hereinafter referred to as KAEDI).Portonbio will offer CMC services for KAEDI's CAR-T cell therapies with i...
2021-06-02 20:10
2033
PharmAbcine to Present at the BIO Digital International Convention 2021
DAEJEON, South Korea, June 2, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company will participate in BIO Digital International Convention. The company will participate in...
2021-06-02 20:00
2795
Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate
INCHEON, South Korea, June 2, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment...
2021-06-02 19:00
2104
CPF launches plant-based "MEAT ZERO", eyeing to make it world's Top 3 alternative meat brand in 3-5 years
BANGKOK, June 2, 2021 /PRNewswire/ -- Charoen Pokphand Foods PLC (CPF) unveils "MEAT ZERO", the meat that is made from plants and manufactured to feel, taste, and appear like real meat thanks to "PLANT-TEC" innovation. The new product, expected to appeal to health-conscious consumers, is affordab...
2021-06-02 17:40
2623
Week's Top Stories
Most Reposted
MTR Lab and ZGC Science City Ltd Establish Ecosystem Partnership
[Picked up by 310 media titles]
2026-03-18 12:00
Nature's Capital: Why Asia's Governments Are Turning to Nature-Based Solutions
[Picked up by 301 media titles]
2026-03-17 08:00HOY Unveils a Powerhouse Line-up of Talent for its Bold New Chapter
[Picked up by 301 media titles]
2026-03-20 09:36
Beijing InfoComm China 2026 Conference Lineup Presents Future of AI in Tech Aligning with the Nation's Next Strategic Five-Year Plan
[Picked up by 296 media titles]
2026-03-18 08:00
Agoda and Gangwon State Join Hands to Elevate Gangwon into a Premier Global Travel Destination
[Picked up by 293 media titles]
2026-03-17 11:29
Most Read
HTCO Launches U.S. Strategic Initiative Led by Chairman Christopher Nixon Cox, Establishes Independent Governance Committee for U.S. Operations
2026-03-13 21:30
7566
Insilico Medicine to Announce 2025 Financial Results on March 30, 2026
2026-03-13 21:59
7104
